1Hoppensteadt DA, Fabbrini N, Bick RL, et al. Laboratory evaluation of the antiphospholipid syndrome [ J ]. Hematol Oncol Clin North Am, 2008 ;22 ( 1 ) : 19-32.
2Wilson WA, Gharavi AE, Koike T, et al. International consensus state- ment on preliminary classification criteria for definite antiphospholipid syndrome: report of art international workshop [J]. Arthritis Rheum, 1999 ;42 : 1309-11.
3Miyakis S, Lockshin MD, Atsumi T, et al. International consensus state- ment on an update of the classification criteria for definite antiphospholip- id syndrome(APS) [ J]. J Thromb Haemost,2006 ;4 ( 2 ) :295-306.
5Krause I, Leibovici L, Blank M, et al. Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis [ J ]. Lupus,2007 ; 16 (3) : 176-80.
6Cuadrado MJ, Khamashta MA, Ballesteros A, et al. Can neurologic mani- festations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature ( J ). Medicine(Baltimore) ,2000 ;79:57-68.
7Sanna G, Bertolaccinil ML, Cuadrado MJ, et al. Central nervous system involvement in the antiphospholipid (Hughes) syndrome [J). Rheuma- tology ,2003 ;42:200-13.
8Sinharay R. Sneddon's syndrome: additional neurological feature in an- tiphospholipid ( Hughes' ) syndrome[J]. Postgrad Med J,2003 ;79:550.
9Verrot D, San-Marco M, Dravet C, et al. Prevalence and signification of antinuclear and anticardiohpin antibodies in patients with epilepsy [J]. Am J Med, 1997 ; 103 : 33-7.
10Cuadrado MJ, Khamashta MA, Hughes GRV. Migraine and stroke in young women[J]. Q J Med,2000;93:317-8.
4Kuruvilla A . Warfarin in antiphospholipid antibody syndrome.Lancet, 2001,27(358) : 1461-1462.
5Jilma B, Kamath S, Lip GY. ABC of antithrombotic therapy : an -tithrombotic therapy in special circtanstances. Ⅱ -In children, thrombophilia, and miscellaneous conditions. BMJ, 2003,326: 93-96.
6Vinatier D, Dufour P, Cosson M, et al. Antiphospholipid syndrome and recurrent miscarriages. Eur J Obstet Gynecol Reprod Biol,2001,96: 37- 50.
7Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus imravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum, 2003, 48: 728-731.
4Miyakis S,Locksin MD,Atsumi T,et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J].J Thromb Haemost,2006,4:295-306.
5Wilson WA,Gharavi AE,Koike T,et al.International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome:report of an international workshop[J].Arthritis Rheum,1999,42:1309-1311.
6Cervera R,Piette JC,Font J,et al,Antiphospholipid syndrome:clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients[J].Arthritis Rheum,2002,46(4):1019-1027.
7Pengo V,Ruffatti A,Legnani C,et al.Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile:a multicenter prospective study[J].Blood,2011,14(9):178-181.
8Mulligan A,McAuley C.Thrombosis and psychosis possible association with the antiphospholipid syndrome and anticardiolipin antibodies[J].Pediatr Int,2009,102(2):61-62.
9Danowski A,de Azevedo MN,de Souza Papi JA,et al.Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus[J].J Rheumatol,2009,36(6):1195-1199.
10Mayer M,Cerovec M,Rado(s) M,et al.Antiphospholipid syndrome and central nervous system[J].Clin Neurol Neurosurg,2010,112(7):602-608.
